Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Cash & Equivalents (2016 - 2025)

OptimizeRx (OPRX) has disclosed Cash & Equivalents for 16 consecutive years, with $23.4 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 74.63% to $23.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $23.4 million through Dec 2025, up 74.63% year-over-year, with the annual reading at $23.4 million for FY2025, 74.63% up from the prior year.
  • Cash & Equivalents hit $23.4 million in Q4 2025 for OptimizeRx, up from $19.5 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $89.0 million in Q1 2022 to a low of $9.8 million in Q2 2023.
  • Historically, Cash & Equivalents has averaged $37.9 million across 5 years, with a median of $17.4 million in 2022.
  • Biggest five-year swings in Cash & Equivalents: soared 705.21% in 2021 and later plummeted 88.78% in 2023.
  • Year by year, Cash & Equivalents stood at $84.7 million in 2021, then crashed by 78.5% to $18.2 million in 2022, then fell by 23.93% to $13.9 million in 2023, then decreased by 3.41% to $13.4 million in 2024, then skyrocketed by 74.63% to $23.4 million in 2025.
  • Business Quant data shows Cash & Equivalents for OPRX at $23.4 million in Q4 2025, $19.5 million in Q3 2025, and $16.6 million in Q2 2025.